Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix
07 janv. 2024 11h00 HE
|
Curevo Vaccine
-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 18h28 HE
|
HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
21 déc. 2023 08h00 HE
|
Curevo Vaccine
SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...
New partnership aims to advance vaccine against MERS coronavirus
21 déc. 2023 07h31 HE
|
Barinthus Biotherapeutics
CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to University of Oxford to develop VTP-500
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
12 déc. 2023 02h05 HE
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
12 déc. 2023 02h00 HE
|
Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
29 nov. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Equine Healthcare Market to Cross USD 972.8 million at a CAGR of 4.3 % by 2028: Transparency Market Research Report Inc.
28 nov. 2023 08h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global equine healthcare market was estimated at a value of US$ 698.7 million in 2020....
Virus-Like Particle Vaccine Market Latest Report 2023-2031 | InsightAce Analytic
16 nov. 2023 02h32 HE
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Virus-Like Particle Vaccine Market- (By...
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
09 nov. 2023 16h05 HE
|
HilleVax, Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...